Overview

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2027-05-01

Target enrollment:

Participant gender:

Summary

This First-in-human (FIH) trial for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with cemiplimab or in combination with docetaxel in patients with advanced or metastasized non-small cell lung cancer (NSCLC). The trial will comprise several cohorts for dose confirmation in monotherapy as well as in combinations.

Phase:

Phase 1

Details

Lead Sponsor:

BioNTech SE

Treatments:

Cemiplimab
Docetaxel